Carl Zeiss Meditec announced that it has become a shareholder of MicroOptx, a privately held company focused on minimally invasive glaucoma surgery (MIGS) devices for surgical treatment of glaucoma. Their surgical technology is designed to provide effective reduction IOP with a simple surgical procedure.
Terms of the deal were not disclosed.
Zeiss said MicroOptx’s MIGS solution will complement its portfolio of equipment and consumables in ophthalmic surgery.
“The investment in MicroOptx will give Zeiss an early position in this new technology designed to increase MIGS adoption for treating glaucoma,” James V. Mazzo, Global President Ophthalmic Devices at Carl Zeiss Meditec, said in a company news release.